Novartis has acquired Parsipanny, N.J.-based drugmaker Medicines Co. for $9.7 billion.
With the deal, announced Nov. 24, Novartis gains Medicine Co.'s cholesterol-lowering drug Inclisiran, which uses a new technique called RNA interference to help especially hard-to-treat patients.
If FDA-approved, Inclisiran is predicted to reach peak annual sales of $4 billion, according to Bloomberg.
"We're hoping to reimagine treatment of the leading global cause of death," Novartis CEO Vas Narasimhan tweeted Nov. 24. " This could be a strong step forward in Novartis' transformation into a focused medicines company."
Shares of Medicines Co. were up by 23 percent in trading before U.S. exchanges opened Nov. 25.
Read the full article here.
More articles on pharmacy:
AHA, CVS Health backed secretive anti-pharma group
EpiPen, Humira among drugs Warren wants to regulate
31 drugmakers at high risk for bankruptcy in 2020